6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Bradyarrhythmia	NNP	bradyarrhythmia	bradyarrhythmia	bradyarrhythmia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Atrioventricular	NNP	atrioventricular	atrioventricular	atrioventricular	N	B-AdverseReaction
Blocks	NNP	blocks	block	block	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
multifocal	JJ	multifocal	multifocal	multifoc	N	I-AdverseReaction
leukoencephalopathy	NN	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Macular	JJ	macular	macular	macular	N	B-AdverseReaction
Edema	NNP	edema	edema	edema	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Posterior	NNP	posterior	posterior	posterior	N	B-AdverseReaction
Reversible	NNP	reversible	reversible	revers	N	I-AdverseReaction
Encephalopathy	NNP	encephalopathy	encephalopathy	encephalopathi	Y	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
Effects	NNS	effects	effect	effect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Liver	NNP	liver	liver	liver	N	B-AdverseReaction
Injury	NNP	injury	injury	injuri	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Novartis	NNP	novartis	novartis	novarti	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
669	CD	669	669	669	N	O
-	:	-	-	-	N	O
6682	CD	6682	6682	6682	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
1212	CD	1212	1212	1212	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
relapsing	VBG	relapsing	relapsing	relaps	N	O
forms	NNS	forms	form	form	N	O
of	IN	of	of	of	N	O
multiple	JJ	multiple	multiple	multipl	N	O
sclerosis	NN	sclerosis	sclerosis	sclerosi	N	O
received	VBD	received	received	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
included	VBD	included	included	includ	N	O
783	CD	783	783	783	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
429	CD	429	429	429	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
1	CD	1	1	1	N	O
year	NN	year	year	year	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
exposure	NN	exposure	exposure	exposur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
was	VBD	was	wa	wa	N	O
equivalent	JJ	equivalent	equivalent	equival	N	O
to	TO	to	to	to	N	O
1716	CD	1716	1716	1716	N	O
person	NN	person	person	person	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
1000	CD	1000	1000	1000	N	O
patients	NNS	patients	patient	patient	N	O
received	VBN	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
all	DT	all	all	all	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
extension	NN	extension	extension	extens	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
4119	CD	4119	4119	4119	N	O
person	NN	person	person	person	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
were	VBD	were	were	were	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
were	VBD	were	were	were	N	O
serum	JJ	serum	serum	serum	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
(	(	(	(	(	N	O
4.7%	CD	4.7%	4.7%	4.7%	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
basal	$	basal	basal	basal	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
lists	NNS	lists	list	list	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
than	IN	than	than	than	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
Reported	NNP	reported	reported	report	N	O
for	IN	for	for	for	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
at	IN	at	at	at	N	O
1%	CD	1%	1%	1%	N	O
Higher	JJR	higher	higher	higher	N	O
Rate	NN	rate	rate	rate	N	O
than	IN	than	than	than	N	O
for	IN	for	for	for	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O

Primary	JJ	primary	primary	primari	N	O
System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
N	NNP	n	n	n	N	O
783	CD	783	783	783	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
773	CD	773	773	773	N	O

Infections	NNS	infections	infection	infect	N	O

Influenza	NNP	influenza	influenza	influenza	Y	B-AdverseReaction
11	CD	11	11	11	N	O
8	CD	8	8	8	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
11	CD	11	11	11	N	O
8	CD	8	8	8	N	O

Bronchitis	NNP	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
8	CD	8	8	8	N	O
5	CD	5	5	5	N	O

Herpes	NNP	herpes	herpes	herp	N	B-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Tinea	NNP	tinea	tinea	tinea	Y	B-AdverseReaction
versicolor	VBD	versicolor	versicolor	versicolor	N	I-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
25	CD	25	25	25	N	O
24	CD	24	24	24	N	O

Migraine	NNP	migraine	migraine	migrain	Y	B-AdverseReaction
6	CD	6	6	6	N	O
4	CD	4	4	4	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
13	CD	13	13	13	N	O
12	CD	12	12	12	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
13	CD	13	13	13	N	O
10	CD	10	10	10	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
11	CD	11	11	11	N	O
10	CD	10	10	10	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
10	CD	10	10	10	N	O
7	CD	7	7	7	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Alopecia	NNP	alopecia	alopecia	alopecia	Y	B-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Actinic	JJ	actinic	actinic	actin	N	B-AdverseReaction
keratosis	NN	keratosis	keratosis	keratosi	Y	I-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Liver	NNP	liver	liver	liver	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
GGT	NNP	ggt	ggt	ggt	Y	I-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
4	CD	4	4	4	N	O

Blood	NNP	blood	blood	blood	N	B-AdverseReaction
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
12	CD	12	12	12	N	O
11	CD	11	11	11	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
9	CD	9	9	9	N	O
7	CD	7	7	7	N	O

Eye	NN	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O

Vision	NN	vision	vision	vision	N	B-AdverseReaction
blurred	VBD	blurred	blurred	blur	N	I-AdverseReaction
4	CD	4	4	4	N	O
2	CD	2	2	2	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
8	CD	8	8	8	N	O
4	CD	4	4	4	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Lymphopenia	NNP	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
7	CD	7	7	7	N	O
1	CD	1	1	1	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Neoplasms	NNP	neoplasms	neoplasm	neoplasm	N	O
benign	NN	benign	benign	benign	N	O
,	,	,	,	,	N	O
malignant	JJ	malignant	malignant	malign	N	O
and	CC	and	and	and	N	O
unspecified	JJ	unspecified	unspecified	unspecifi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
cysts	NNS	cysts	cyst	cyst	N	O
and	CC	and	and	and	N	O
polyps	NNS	polyps	polyp	polyp	Y	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
papilloma	VBD	papilloma	papilloma	papilloma	Y	I-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Basal	NNP	basal	basal	basal	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	VBD	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
eczema	NN	eczema	eczema	eczema	Y	B-AdverseReaction
and	CC	and	and	and	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
but	CC	but	but	but	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
meet	VB	meet	meet	meet	N	O
the	DT	the	the	the	N	O
reporting	NN	reporting	reporting	report	N	O
rate	NN	rate	rate	rate	N	O
criteria	NNS	criteria	criterion	criteria	N	O
for	IN	for	for	for	N	O
inclusion	NN	inclusion	inclusion	inclus	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
difference	NN	difference	difference	differ	N	O
was	VBD	was	wa	wa	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	NN	adverse	adverse	advers	N	O

reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
(	(	(	(	(	N	O
versus	NN	versus	versus	versu	N	O
interferon	NN	interferon	interferon	interferon	N	O
beta	SYM	beta	beta	beta	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
a	DT	a	a	a	N	O
)	)	)	)	)	N	O
study	NN	study	study	studi	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
in	IN	in	in	in	N	O
Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Events	NNS	events	event	event	N	O

Vascular	JJ	vascular	vascular	vascular	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ischemic	JJ	ischemic	ischemic	ischem	N	B-AdverseReaction
and	CC	and	and	and	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
strokes	NNS	strokes	stroke	stroke	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
arterial	JJ	arterial	arterial	arteri	N	I-AdverseReaction
occlusive	JJ	occlusive	occlusive	occlus	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
premarketing	VBG	premarketing	premarketing	premarket	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
doses	NNS	doses	dos	dose	N	O
(	(	(	(	(	N	O
1.25	CD	1.25	1.25	1.25	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
MS	NNP	ms	m	ms	Y	O
.	.	.	.	.	N	O

Similar	JJ	similar	similar	similar	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
setting	NN	setting	setting	set	N	O
although	IN	although	although	although	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

Lymphomas	NN	lymphomas	lymphoma	lymphoma	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
premarketing	VBG	premarketing	premarketing	premarket	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
setting	NN	setting	setting	set	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
remains	VBZ	remains	remains	remain	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
atrioventricular	JJ	atrioventricular	atrioventricular	atrioventricular	N	B-AdverseReaction
conduction	NN	conduction	conduction	conduct	N	I-AdverseReaction
after	IN	after	after	after	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
:	:	:	:	:	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
recent	JJ	recent	recent	recent	N	O
CBC	NNP	cbc	cbc	cbc	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
available	JJ	available	available	avail	N	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
start	VB	start	start	start	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
multifocal	JJ	multifocal	multifocal	multifoc	N	I-AdverseReaction
leukoencephalopathy	NN	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)	)	)	)	)	N	O
;	:	;	;	;	N	O
Withhold	VBN	withhold	withhold	withhold	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
sign	NN	sign	sign	sign	N	O
or	CC	or	or	or	N	O
symptom	JJ	symptom	symptom	symptom	N	O
suggestive	NN	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
:	:	:	:	:	N	O
Perform	VB	perform	perform	perform	N	O
an	DT	an	an	an	N	O
examination	NN	examination	examination	examin	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
fundus	NN	fundus	fundus	fundu	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
macula	NN	macula	macula	macula	N	O
before	IN	before	before	befor	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
initiation	NN	initiation	initiation	initi	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	VBP	mellitus	mellitus	mellitu	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Posterior	NNP	posterior	posterior	posterior	N	B-AdverseReaction
reversible	JJ	reversible	reversible	revers	N	I-AdverseReaction
encephalopathy	JJ	encephalopathy	encephalopathy	encephalopathi	Y	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PRES	NNP	pres	pres	pre	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
If	IN	if	if	if	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Decrease	NNP	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
tests	NNS	tests	test	test	N	I-AdverseReaction
(	(	(	(	(	N	O
PFT	NNP	pft	pft	pft	N	I-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Obtain	NN	obtain	obtain	obtain	N	O
PFT	NNP	pft	pft	pft	N	O
when	WRB	when	when	when	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Liver	NNP	liver	liver	liver	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
:	:	:	:	:	N	O
liver	NN	liver	liver	liver	N	O
enzyme	VBP	enzyme	enzyme	enzym	N	O
results	NNS	results	result	result	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
available	JJ	available	available	avail	N	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
.	.	.	.	.	N	O

Discontinue	NN	discontinue	discontinue	discontinu	N	O
if	IN	if	if	if	N	O
significant	JJ	significant	significant	signific	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
occurs	NNS	occurs	occurs	occur	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
childbearing	VBG	childbearing	childbearing	childbear	N	O
potential	NN	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
use	VB	use	use	use	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
stopping	VBG	stopping	stopping	stop	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

Blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
(	(	(	(	(	N	O
BP	NNP	bp	bp	bp	Y	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
BP	NNP	bp	bp	bp	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Bradyarrhythmia	NN	bradyarrhythmia	bradyarrhythmia	bradyarrhythmia	Y	O

and	CC	and	and	and	N	O
Atrioventricular	NNP	atrioventricular	atrioventricular	atrioventricular	N	O
Blocks	NNP	blocks	block	block	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
bradyarrhythmia	NN	bradyarrhythmia	bradyarrhythmia	bradyarrhythmia	Y	O
and	CC	and	and	and	N	O
atrioventricular	NN	atrioventricular	atrioventricular	atrioventricular	N	O
(	(	(	(	(	N	O
AV	NNP	av	av	av	N	O
)	)	)	)	)	N	O
blocks	NNS	blocks	block	block	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
during	IN	during	during	dure	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
treatment	NN	treatment	treatment	treatment	N	O
initiation	NN	initiation	initiation	initi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
Heart	NNP	heart	heart	heart	N	O
Rate	NNP	rate	rate	rate	N	O

After	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
starts	VBZ	starts	start	start	N	O
within	IN	within	within	within	N	O
an	DT	an	an	an	N	O
hour	NN	hour	hour	hour	N	O
.	.	.	.	.	N	O

On	IN	on	on	on	N	O
Day	NNP	day	day	day	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
maximum	JJ	maximum	maximum	maximum	N	O
decline	NN	decline	decline	declin	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
generally	RB	generally	generally	gener	N	O
occurs	VBZ	occurs	occurs	occur	N	O
within	IN	within	within	within	N	O
6	CD	6	6	6	N	O
hours	NNS	hours	hour	hour	N	O
and	CC	and	and	and	N	O
recovers	NNS	recovers	recovers	recov	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
not	RB	not	not	not	N	O
to	TO	to	to	to	N	O
baseline	NN	baseline	baseline	baselin	N	O
levels	NNS	levels	level	level	N	O
,	,	,	,	,	N	O
by	IN	by	by	by	N	O
8	CD	8	8	8	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
hours	NNS	hours	hour	hour	N	O
postdose	RB	postdose	postdose	postdos	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
physiological	JJ	physiological	physiological	physiolog	N	O
diurnal	JJ	diurnal	diurnal	diurnal	N	O
variation	NN	variation	variation	variat	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
second	JJ	second	second	second	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
within	IN	within	within	within	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
period	NN	period	period	period	N	O
is	VBZ	is	is	is	N	O
more	RBR	more	more	more	N	O
pronounced	JJ	pronounced	pronounced	pronounc	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
decrease	NN	decrease	decrease	decreas	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
6	CD	6	6	6	N	O
hours	NNS	hours	hour	hour	N	O
.	.	.	.	.	N	O

Heart	NNP	heart	heart	heart	N	B-AdverseReaction
rates	NNS	rates	rate	rate	N	I-AdverseReaction
below	IN	below	below	below	N	I-AdverseReaction
40	CD	40	40	40	N	I-AdverseReaction
beats	NNS	beats	beat	beat	N	I-AdverseReaction
per	IN	per	per	per	N	I-AdverseReaction
minute	NN	minute	minute	minut	N	I-AdverseReaction
were	VBD	were	were	were	N	O
rarely	RB	rarely	rarely	rare	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	I-AdverseReaction
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
experienced	JJ	experienced	experienced	experienc	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
palpitations	NNS	palpitations	palpitation	palpit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
chest	JJS	chest	chest	chest	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
that	WDT	that	that	that	N	O
usually	RB	usually	usually	usual	N	O
resolved	VBD	resolved	resolved	resolv	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
on	IN	on	on	on	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
further	JJ	further	further	further	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
this	DT	this	this	thi	N	O
change	NN	change	change	chang	N	O
is	VBZ	is	is	is	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
smaller	JJR	smaller	smaller	smaller	N	O
magnitude	NN	magnitude	magnitude	magnitud	N	O
than	IN	than	than	than	N	O
that	DT	that	that	that	N	O
observed	VBD	observed	observed	observ	N	O
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

With	IN	with	with	with	N	O
continued	JJ	continued	continued	continu	N	O
dosing	NN	dosing	dosing	dose	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
returns	NNS	returns	return	return	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
within	IN	within	within	within	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
of	IN	of	of	of	N	O
chronic	JJ	chronic	chronic	chronic	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Atrioventricular	JJ	atrioventricular	atrioventricular	atrioventricular	N	O
Blocks	NNS	blocks	block	block	N	O

Initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
treatment	NN	treatment	treatment	treatment	N	O
has	VBZ	has	ha	ha	N	O
resulted	VBN	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
transient	JJ	transient	transient	transient	N	B-Severity
AV	NNP	av	av	av	N	B-AdverseReaction
conduction	NN	conduction	conduction	conduct	N	I-AdverseReaction
delays	NNS	delays	delay	delay	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
first	RB	first	first	first	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
degree	NN	degree	degree	degre	N	I-AdverseReaction
AV	NNP	av	av	av	N	I-AdverseReaction
block	NN	block	block	block	N	I-AdverseReaction
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
4.7%	CD	4.7%	4.7%	4.7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
and	CC	and	and	and	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
697	CD	697	697	697	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
available	JJ	available	available	avail	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
hour	NN	hour	hour	hour	N	O
Holter	NNP	holter	holter	holter	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
data	NNS	data	data	data	N	O
after	IN	after	after	after	N	O
their	PRP$	their	their	their	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
351	CD	351	351	351	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
and	CC	and	and	and	N	O
N	NNP	n	n	n	N	O
346	CD	346	346	346	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
second	JJ	second	second	second	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
degree	NN	degree	degree	degre	N	I-AdverseReaction
AV	NNP	av	av	av	N	I-AdverseReaction
blocks	NNS	blocks	block	block	N	I-AdverseReaction
(	(	(	(	(	N	O
Mobitz	NNP	mobitz	mobitz	mobitz	N	I-AdverseReaction
Types	NNP	types	type	type	N	I-AdverseReaction
I	PRP	i	i	i	N	I-AdverseReaction
[	VBP	[	[	[	N	O
Wenckebach	NNP	wenckebach	wenckebach	wenckebach	Y	I-AdverseReaction
]	NNP	]	]	]	N	O
or	CC	or	or	or	N	O
2	CD	2	2	2	N	B-AdverseReaction
:	:	:	:	:	N	I-AdverseReaction
1	CD	1	1	1	N	I-AdverseReaction
AV	NNP	av	av	av	N	I-AdverseReaction
blocks	NNS	blocks	block	block	N	I-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
14	CD	14	14	14	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
,	,	,	,	,	N	O
7	CD	7	7	7	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
2	CD	2	2	2	N	B-AdverseReaction
:	:	:	:	:	N	I-AdverseReaction
1	CD	1	1	1	N	I-AdverseReaction
AV	NNP	av	av	av	N	I-AdverseReaction
block	NN	block	block	block	N	I-AdverseReaction
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
6	CD	6	6	6	N	O
hours	NNS	hours	hour	hour	N	O
postdose	JJ	postdose	postdose	postdos	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
patients	NNS	patients	patient	patient	N	O
after	IN	after	after	after	N	O
6	CD	6	6	6	N	O
hours	NNS	hours	hour	hour	N	O
postdose	RB	postdose	postdose	postdos	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
second	JJ	second	second	second	N	B-AdverseReaction
degree	NN	degree	degree	degre	N	I-AdverseReaction
AV	NNP	av	av	av	N	I-AdverseReaction
blocks	NNS	blocks	block	block	N	I-AdverseReaction
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
were	VBD	were	were	were	N	O
Mobitz	NNP	mobitz	mobitz	mobitz	N	I-AdverseReaction
Type	NNP	type	type	type	N	I-AdverseReaction
I	PRP	i	i	i	N	I-AdverseReaction
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
12	CD	12	12	12	N	O
hours	NNS	hours	hour	hour	N	O
postdose	RB	postdose	postdose	postdos	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
conduction	NN	conduction	conduction	conduct	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
were	VBD	were	were	were	N	O
usually	RB	usually	usually	usual	N	O
transient	JJ	transient	transient	transient	N	B-Severity
and	CC	and	and	and	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
resolved	VBD	resolved	resolved	resolv	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
on	IN	on	on	on	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
they	PRP	they	they	they	N	O
occasionally	RB	occasionally	occasionally	occasion	N	O
required	VBD	required	required	requir	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
atropine	NN	atropine	atropine	atropin	N	O
or	CC	or	or	or	N	O
isoproterenol	NN	isoproterenol	isoproterenol	isoproterenol	N	O
.	.	.	.	.	N	O

Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
setting	NN	setting	setting	set	N	O
,	,	,	,	,	N	O
third	JJ	third	third	third	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
degree	NN	degree	degree	degre	N	I-AdverseReaction
AV	NNP	av	av	av	N	I-AdverseReaction
block	NN	block	block	block	N	I-AdverseReaction
and	CC	and	and	and	N	O
AV	NNP	av	av	av	N	B-AdverseReaction
block	NN	block	block	block	N	I-AdverseReaction
with	IN	with	with	with	N	O
junctional	JJ	junctional	junctional	junction	N	B-AdverseReaction
escape	NN	escape	escape	escap	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
hour	NN	hour	hour	hour	N	O
observation	NN	observation	observation	observ	N	O
period	NN	period	period	period	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

Isolated	VBN	isolated	isolated	isol	N	O
delayed	JJ	delayed	delayed	delay	N	O
onset	NN	onset	onset	onset	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
transient	JJ	transient	transient	transient	N	B-Severity
asystole	NN	asystole	asystole	asystol	Y	B-AdverseReaction
and	CC	and	and	and	N	O
unexplained	JJ	unexplained	unexplained	unexplain	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
confounded	VBN	confounded	confounded	confound	N	O
by	IN	by	by	by	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
preexisting	VBG	preexisting	preexisting	preexist	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
is	VBZ	is	is	is	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Infections	NNS	infections	infection	infect	N	O

Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Infections	NNS	infections	infection	infect	N	O

GILENYA	NNP	gilenya	gilenya	gilenya	N	O
causes	VBZ	causes	cause	caus	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
reduction	NN	reduction	reduction	reduct	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
lymphocyte	NN	lymphocyte	lymphocyte	lymphocyt	N	I-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
to	TO	to	to	to	N	O
20%	CD	20%	20%	20%	N	B-Severity
-	:	-	-	-	N	I-Severity
30%	CD	30%	30%	30%	N	I-Severity
of	IN	of	of	of	N	I-Severity
baseline	NN	baseline	baseline	baselin	N	I-Severity
values	NNS	values	value	valu	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
reversible	JJ	reversible	reversible	revers	N	B-Severity
sequestration	NN	sequestration	sequestration	sequestr	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
lymphoid	JJ	lymphoid	lymphoid	lymphoid	N	I-AdverseReaction
tissues	NNS	tissues	tissue	tissu	N	I-AdverseReaction
.	.	.	.	.	N	O

GILENYA	NNP	gilenya	gilenya	gilenya	N	O
may	MD	may	may	may	N	O
therefore	VB	therefore	therefore	therefor	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
in	IN	in	in	in	N	O
nature	NN	nature	nature	natur	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
recent	JJ	recent	recent	recent	N	O
CBC	NNP	cbc	cbc	cbc	Y	O
(	(	(	(	(	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
within	IN	within	within	within	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
or	CC	or	or	or	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
prior	JJ	prior	prior	prior	N	O
therapy	NN	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
suspending	VBG	suspending	suspending	suspend	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
reassess	VB	reassess	reassess	reassess	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
reinitiation	NN	reinitiation	reinitiation	reiniti	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
the	DT	the	the	the	N	O
elimination	NN	elimination	elimination	elimin	N	O
of	IN	of	of	of	N	O
fingolimod	NN	fingolimod	fingolimod	fingolimod	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
may	MD	may	may	may	N	O
take	VB	take	take	take	N	O
up	RP	up	up	up	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
continue	VBP	continue	continue	continu	N	O
monitoring	VBG	monitoring	monitoring	monitor	N	O
for	IN	for	for	for	N	O
infections	NNS	infections	infection	infect	N	O
throughout	IN	throughout	throughout	throughout	N	O
this	DT	this	this	thi	N	O
period	NN	period	period	period	N	O
.	.	.	.	.	N	O

Instruct	NN	instruct	instruct	instruct	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
to	TO	to	to	to	N	O
report	VB	report	report	report	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
acute	NN	acute	acute	acut	N	O
or	CC	or	or	or	N	O
chronic	JJ	chronic	chronic	chronic	N	O
infections	NNS	infections	infection	infect	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
start	VB	start	start	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
infection	NN	infection	infection	infect	Y	O
(	(	(	(	(	N	O
s	NN	s	s	s	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
resolved	VBN	resolved	resolved	resolv	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
MS	NNP	ms	m	ms	Y	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
72%	CD	72%	72%	72%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
group	NN	group	group	group	N	O
versus	VBD	versus	versus	versu	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Herpes	NNP	herpes	herpes	herp	N	O
Viral	NNP	viral	viral	viral	N	O
Infections	NNP	infections	infection	infect	N	O

In	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
herpetic	JJ	herpetic	herpetic	herpet	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
9%	CD	9%	9%	9%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
died	VBD	died	died	die	N	B-AdverseReaction
of	IN	of	of	of	N	O
herpetic	JJ	herpetic	herpetic	herpet	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
during	IN	during	during	dure	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
death	NN	death	death	death	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	B-AdverseReaction
primary	JJ	primary	primary	primari	N	I-AdverseReaction
herpes	NNS	herpes	herpes	herp	N	I-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
to	TO	to	to	to	N	O
herpes	VB	herpes	herpes	herp	N	B-AdverseReaction
simplex	JJ	simplex	simplex	simplex	N	I-AdverseReaction
encephalitis	NN	encephalitis	encephalitis	enceph	Y	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
both	DT	both	both	both	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
taking	VBG	taking	taking	take	N	O
a	DT	a	a	a	N	O
1.25	CD	1.25	1.25	1.25	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
fingolimod	NN	fingolimod	fingolimod	fingolimod	N	O
(	(	(	(	(	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
received	VBN	received	received	receiv	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
therapy	NN	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
suspected	JJ	suspected	suspected	suspect	N	O
MS	NNP	ms	m	ms	Y	O
relapses	NNS	relapses	relapse	relaps	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	B-AdverseReaction
varicella	NN	varicella	varicella	varicella	Y	I-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
and	CC	and	and	and	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
simplex	JJ	simplex	simplex	simplex	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
encephalitis	NN	encephalitis	encephalitis	enceph	Y	B-AdverseReaction
and	CC	and	and	and	N	O
multiorgan	JJ	multiorgan	multiorgan	multiorgan	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
setting	NN	setting	setting	set	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Include	NNP	include	include	includ	N	O
disseminated	VBD	disseminated	disseminated	dissemin	N	O
herpetic	JJ	herpetic	herpetic	herpet	N	O
infections	NNS	infections	infection	infect	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
differential	JJ	differential	differential	differenti	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
and	CC	and	and	and	N	O
present	JJ	present	present	present	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
atypical	JJ	atypical	atypical	atyp	N	O
MS	NNP	ms	m	ms	Y	O
relapse	NN	relapse	relapse	relaps	N	O
or	CC	or	or	or	N	O
multiorgan	JJ	multiorgan	multiorgan	multiorgan	N	O
failure	NN	failure	failure	failur	N	O
.	.	.	.	.	N	O

Cryptococcal	JJ	cryptococcal	cryptococcal	cryptococc	N	O
infections	NNS	infections	infection	infect	N	O

Cryptococcal	JJ	cryptococcal	cryptococcal	cryptococc	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
cryptococcal	JJ	cryptococcal	cryptococcal	cryptococc	N	B-AdverseReaction
meningitis	NN	meningitis	meningitis	mening	Y	I-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
setting	NN	setting	setting	set	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
signs	NNS	signs	sign	sign	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
cryptococcal	JJ	cryptococcal	cryptococcal	cryptococc	N	O
meningitis	NN	meningitis	meningitis	mening	Y	O
should	MD	should	should	should	N	O
undergo	VB	undergo	undergo	undergo	N	O
prompt	JJ	prompt	prompt	prompt	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Prior	NNP	prior	prior	prior	N	O
and	CC	and	and	and	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Antineoplastic	NNP	antineoplastic	antineoplastic	antineoplast	N	O
,	,	,	,	,	N	O
Immunosuppressive	NNP	immunosuppressive	immunosuppressive	immunosuppress	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
Immune	NNP	immune	immune	immun	N	O
-	:	-	-	-	N	O
Modulating	VBG	modulating	modulating	modul	N	O
Therapies	NNS	therapies	therapy	therapi	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
receive	VB	receive	receive	receiv	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
antineoplastic	JJ	antineoplastic	antineoplastic	antineoplast	N	O
,	,	,	,	,	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
modulating	NN	modulating	modulating	modul	N	O
therapies	NNS	therapies	therapy	therapi	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
MS	NNP	ms	m	ms	Y	O
.	.	.	.	.	N	O

Concomitant	NNP	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
therapies	NNS	therapies	therapy	therapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
also	RB	also	also	also	N	O
with	IN	with	with	with	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
would	MD	would	would	would	N	O
be	VB	be	be	be	N	O
expected	VBN	expected	expected	expect	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
switching	VBG	switching	switching	switch	N	O
to	TO	to	to	to	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
from	IN	from	from	from	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
modulating	NN	modulating	modulating	modul	N	O
or	CC	or	or	or	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
effects	NNS	effects	effect	effect	N	O
and	CC	and	and	and	N	O
their	PRP$	their	their	their	N	O
mode	NN	mode	mode	mode	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
unintended	JJ	unintended	unintended	unintend	N	O
additive	JJ	additive	additive	addit	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
effects	NNS	effects	effect	effect	N	O
.	.	.	.	.	N	O

Varicella	NNP	varicella	varicella	varicella	Y	O
Zoster	NNP	zoster	zoster	zoster	N	O
Virus	NNP	virus	virus	viru	N	O
Antibody	NNP	antibody	antibody	antibodi	N	O
Testing	NNP	testing	testing	test	N	O
Vaccination	NNP	vaccination	vaccination	vaccin	Y	O

Patients	NNS	patients	patient	patient	N	O
without	IN	without	without	without	N	O
a	DT	a	a	a	N	O
healthcare	JJ	healthcare	healthcare	healthcar	N	O
professional	NN	professional	professional	profession	N	O
confirmed	VBD	confirmed	confirmed	confirm	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
chickenpox	NN	chickenpox	chickenpox	chickenpox	Y	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
documentation	NN	documentation	documentation	document	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
full	JJ	full	full	full	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
vaccination	NN	vaccination	vaccination	vaccin	Y	O
against	IN	against	against	against	N	O
varicella	NN	varicella	varicella	varicella	Y	O
zoster	NN	zoster	zoster	zoster	N	O
virus	NN	virus	virus	viru	N	O
(	(	(	(	(	N	O
VZV	NNP	vzv	vzv	vzv	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
VZV	NNP	vzv	vzv	vzv	N	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

VZV	NNP	vzv	vzv	vzv	N	O
vaccination	NN	vaccination	vaccination	vaccin	Y	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
-	:	-	-	-	N	O
negative	JJ	negative	negative	neg	N	O
patients	NNS	patients	patient	patient	N	O
is	VBZ	is	is	is	N	O
recommended	JJ	recommended	recommended	recommend	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
commencing	VBG	commencing	commencing	commenc	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
,	,	,	,	,	N	O
following	VBG	following	following	follow	N	O
which	WDT	which	which	which	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
postponed	VBN	postponed	postponed	postpon	N	O
for	IN	for	for	for	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
to	TO	to	to	to	N	O
allow	VB	allow	allow	allow	N	O
the	DT	the	the	the	N	O
full	JJ	full	full	full	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
vaccination	NN	vaccination	vaccination	vaccin	Y	O
to	TO	to	to	to	N	O
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Progressive	JJ	progressive	progressive	progress	N	O
Multifocal	NNP	multifocal	multifocal	multifoc	N	O
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O

A	DT	a	a	a	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
multifocal	JJ	multifocal	multifocal	multifoc	N	I-AdverseReaction
leukoencephalopathy	NN	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
probable	JJ	probable	probable	probabl	N	B-Factor
PML	NNP	pml	pml	pml	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MS	NNP	ms	m	ms	Y	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
post	NN	post	post	post	N	O
marketing	NN	marketing	marketing	market	N	O
setting	NN	setting	setting	set	N	O
.	.	.	.	.	N	O

PML	NNP	pml	pml	pml	N	B-AdverseReaction
is	VBZ	is	is	is	N	O
an	DT	an	an	an	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
viral	JJ	viral	viral	viral	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
brain	NN	brain	brain	brain	N	I-AdverseReaction
caused	VBN	caused	caused	caus	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
JC	NNP	jc	jc	jc	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
(	(	(	(	(	N	O
JCV	NNP	jcv	jcv	jcv	N	B-AdverseReaction
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
typically	RB	typically	typically	typic	N	B-Factor
only	RB	only	only	onli	N	O
occurs	VBZ	occurs	occurs	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
immunocompromised	VBN	immunocompromised	immunocompromised	immunocompromis	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
that	IN	that	that	that	N	O
usually	RB	usually	usually	usual	N	B-Factor
leads	VBZ	leads	lead	lead	N	O
to	TO	to	to	to	N	O
death	NN	death	death	death	Y	B-AdverseReaction
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	B-Severity
disability	NN	disability	disability	disabl	Y	B-AdverseReaction
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
after	IN	after	after	after	N	O
taking	VBG	taking	taking	take	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
for	IN	for	for	for	N	O
approximately	RB	approximately	approximately	approxim	N	O
2.5	CD	2.5	2.5	2.5	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
patient	NN	patient	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
probable	JJ	probable	probable	probabl	N	B-Factor
PML	NNP	pml	pml	pml	N	B-AdverseReaction
after	IN	after	after	after	N	O
taking	VBG	taking	taking	take	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
for	IN	for	for	for	N	O
approximately	RB	approximately	approximately	approxim	N	O
4	CD	4	4	4	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
probable	JJ	probable	probable	probabl	N	B-Factor
PML	NNP	pml	pml	pml	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
MRI	NNP	mri	mri	mri	Y	O
findings	NNS	findings	finding	find	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
JCV	NNP	jcv	jcv	jcv	N	B-AdverseReaction
DNA	NNP	dna	dna	dna	N	O
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
CSF	NNP	csf	csf	csf	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	B-Negation
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
specific	JJ	specific	specific	specif	N	O
to	TO	to	to	to	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
no	DT	no	no	no	N	O
other	JJ	other	other	other	N	O
identified	VBN	identified	identified	identifi	N	O
systemic	JJ	systemic	systemic	system	N	O
medical	JJ	medical	medical	medic	N	O
conditions	NNS	conditions	condition	condit	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
compromised	VBN	compromised	compromised	compromis	N	B-AdverseReaction
immune	NN	immune	immune	immun	N	I-AdverseReaction
system	NN	system	system	system	N	I-AdverseReaction
function	NN	function	function	function	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
not	RB	not	not	not	N	O
previously	RB	previously	previously	previous	N	O
been	VBN	been	been	been	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
natalizumab	NN	natalizumab	natalizumab	natalizumab	N	B-Negation
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
has	VBZ	has	ha	ha	N	O
a	DT	a	a	a	N	O
known	VBN	known	known	known	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
not	RB	not	not	not	N	O
taking	VBG	taking	taking	take	N	O
any	DT	any	any	ani	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
or	CC	or	or	or	N	O
immunomodulatory	JJ	immunomodulatory	immunomodulatory	immunomodulatori	N	O
medications	NNS	medications	medication	medic	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
sign	NN	sign	sign	sign	N	O
or	CC	or	or	or	N	O
symptom	JJ	symptom	symptom	symptom	N	O
suggestive	NN	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	O
,	,	,	,	,	N	O
withhold	VBD	withhold	withhold	withhold	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
and	CC	and	and	and	N	O
perform	VB	perform	perform	perform	N	O
an	DT	an	an	an	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

MRI	NNP	mri	mri	mri	Y	O
signs	NNS	signs	sign	sign	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
apparent	JJ	apparent	apparent	appar	N	O
before	RB	before	before	befor	N	O
clinical	JJ	clinical	clinical	clinic	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

Typical	JJ	typical	typical	typic	N	B-Factor
symptoms	NNS	symptoms	symptom	symptom	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
are	VBP	are	are	are	N	O
diverse	JJ	diverse	diverse	divers	N	O
,	,	,	,	,	N	O
progress	NN	progress	progress	progress	N	O
over	IN	over	over	over	N	O
days	NNS	days	day	day	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
include	VBP	include	include	includ	N	O
progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
on	IN	on	on	on	N	I-AdverseReaction
one	CD	one	one	one	N	I-AdverseReaction
side	NN	side	side	side	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
or	CC	or	or	or	N	O
clumsiness	NN	clumsiness	clumsiness	clumsi	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
limbs	NNS	limbs	limb	limb	N	I-AdverseReaction
,	,	,	,	,	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
thinking	NN	thinking	thinking	think	N	I-AdverseReaction
,	,	,	,	,	N	O
memory	NN	memory	memory	memori	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
orientation	NN	orientation	orientation	orient	N	I-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
confusion	NN	confusion	confusion	confus	Y	B-AdverseReaction
and	CC	and	and	and	N	O
personality	NN	personality	personality	person	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Macular	JJ	macular	macular	macular	N	O
Edema	NN	edema	edema	edema	Y	O

Fingolimod	NNP	fingolimod	fingolimod	fingolimod	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
.	.	.	.	.	N	O

Perform	VB	perform	perform	perform	N	O
an	DT	an	an	an	N	O
examination	NN	examination	examination	examin	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
fundus	NN	fundus	fundus	fundu	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
macula	NN	macula	macula	macula	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
before	IN	before	before	befor	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
again	RB	again	again	again	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
again	RB	again	again	again	N	O
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
time	NN	time	time	time	N	O
after	IN	after	after	after	N	O
a	DT	a	a	a	N	O
patient	JJ	patient	patient	patient	N	O
reports	NNS	reports	report	report	N	O
visual	JJ	visual	visual	visual	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
clinical	JJ	clinical	clinical	clinic	N	O
development	NN	development	development	develop	N	O
program	NN	program	program	program	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
multiple	JJ	multiple	multiple	multipl	N	O
sclerosis	NN	sclerosis	sclerosis	sclerosi	N	O
,	,	,	,	,	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
799	CD	799	799	799	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
fingolimod	JJ	fingolimod	fingolimod	fingolimod	N	O
1.25	CD	1.25	1.25	1.25	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
783	CD	783	783	783	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
773	CD	773	773	773	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
excluded	VBD	excluded	excluded	exclud	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
known	VBN	known	known	known	N	O
risk	NN	risk	risk	risk	N	O
factor	NN	factor	factor	factor	N	O
for	IN	for	for	for	N	O
macular	JJ	macular	macular	macular	N	O
edema	NN	edema	edema	edema	Y	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
below	IN	below	below	below	N	O
Macular	NNP	macular	macular	macular	N	O
Edema	NNP	edema	edema	edema	Y	O
in	IN	in	in	in	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
History	NNP	history	history	histori	N	O
of	IN	of	of	of	N	O
Uveitis	NNP	uveitis	uveitis	uveiti	Y	O
or	CC	or	or	or	N	O
Diabetes	NNP	diabetes	diabetes	diabet	Y	O
Mellitus	NNP	mellitus	mellitus	mellitu	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
included	VBD	included	included	includ	N	O
blurred	JJ	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
and	CC	and	and	and	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
.	.	.	.	.	N	O

Routine	JJ	routine	routine	routin	N	O
ophthalmological	JJ	ophthalmological	ophthalmological	ophthalmolog	N	O
examination	NN	examination	examination	examin	N	O
detected	VBD	detected	detected	detect	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
no	DT	no	no	no	N	B-Negation
visual	JJ	visual	visual	visual	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
.	.	.	.	.	N	O

Macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
generally	RB	generally	generally	gener	N	O
partially	RB	partially	partially	partial	N	O
or	CC	or	or	or	N	O
completely	RB	completely	completely	complet	N	O
resolved	VBN	resolved	resolved	resolv	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
treatment	NN	treatment	treatment	treatment	N	O
after	IN	after	after	after	N	O
drug	NN	drug	drug	drug	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
residual	JJ	residual	residual	residu	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
even	RB	even	even	even	N	O
after	IN	after	after	after	N	O
resolution	NN	resolution	resolution	resolut	N	O
of	IN	of	of	of	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
.	.	.	.	.	N	O

Macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
setting	NN	setting	setting	set	N	O
,	,	,	,	,	N	O
usually	RB	usually	usually	usual	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Continuation	NN	continuation	continuation	continu	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
decision	NN	decision	decision	decis	N	O
on	IN	on	on	on	N	O
whether	IN	whether	whether	whether	N	O
or	CC	or	or	or	N	O
not	RB	not	not	not	N	O
to	TO	to	to	to	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
include	VB	include	include	includ	N	O
an	DT	an	an	an	N	O
assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
benefits	NNS	benefits	benefit	benefit	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
individual	JJ	individual	individual	individu	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
after	IN	after	after	after	N	O
rechallenge	NN	rechallenge	rechallenge	rechalleng	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
.	.	.	.	.	N	O

Macular	JJ	macular	macular	macular	N	O
Edema	NNP	edema	edema	edema	Y	O
in	IN	in	in	in	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
History	NNP	history	history	histori	N	O
of	IN	of	of	of	N	O
Uveitis	NNP	uveitis	uveitis	uveiti	Y	O
or	CC	or	or	or	N	O
Diabetes	VBZ	diabetes	diabetes	diabet	Y	O
Mellitus	NNP	mellitus	mellitus	mellitu	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
during	IN	during	during	dure	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
is	VBZ	is	is	is	N	O
also	RB	also	also	also	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
MS	NNP	ms	m	ms	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
combined	JJ	combined	combined	combin	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
fingolimod	NN	fingolimod	fingolimod	fingolimod	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
macular	JJ	macular	macular	macular	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
20%	CD	20%	20%	20%	N	O
in	IN	in	in	in	N	O
MS	NNP	ms	m	ms	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
uveitis	JJ	uveitis	uveitis	uveiti	Y	O
versus	NN	versus	versus	versu	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
without	IN	without	without	without	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	O
.	.	.	.	.	N	O

GILENYA	NNP	gilenya	gilenya	gilenya	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
tested	VBN	tested	tested	test	N	O
in	IN	in	in	in	N	O
MS	NNP	ms	m	ms	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
examination	NN	examination	examination	examin	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
fundus	NN	fundus	fundus	fundu	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
macula	NN	macula	macula	macula	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
MS	NNP	ms	m	ms	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	VBP	mellitus	mellitus	mellitu	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
regular	JJ	regular	regular	regular	N	O
follow	VB	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	RP	up	up	up	N	O
examinations	NNS	examinations	examination	examin	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Posterior	NNP	posterior	posterior	posterior	N	O
Reversible	NNP	reversible	reversible	revers	N	O
Encephalopathy	NNP	encephalopathy	encephalopathy	encephalopathi	Y	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
rare	JJ	rare	rare	rare	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
posterior	JJ	posterior	posterior	posterior	N	B-AdverseReaction
reversible	JJ	reversible	reversible	revers	N	I-AdverseReaction
encephalopathy	JJ	encephalopathy	encephalopathy	encephalopathi	Y	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PRES	NNP	pres	pres	pre	N	B-AdverseReaction
)	)	)	)	)	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
reported	VBD	reported	reported	report	N	O
included	JJ	included	included	includ	N	O
sudden	JJ	sudden	sudden	sudden	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
altered	VBD	altered	altered	alter	N	B-AdverseReaction
mental	JJ	mental	mental	mental	N	I-AdverseReaction
status	NN	status	status	statu	N	I-AdverseReaction
,	,	,	,	,	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
disturbances	NNS	disturbances	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
.	.	.	.	.	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
PRES	NNP	pres	pres	pre	N	B-AdverseReaction
are	VBP	are	are	are	N	O
usually	RB	usually	usually	usual	N	O
reversible	JJ	reversible	reversible	revers	N	O
but	CC	but	but	but	N	O
may	MD	may	may	may	N	B-Factor
evolve	VB	evolve	evolve	evolv	N	O
into	IN	into	into	into	N	O
ischemic	JJ	ischemic	ischemic	ischem	N	B-AdverseReaction
stroke	NN	stroke	stroke	stroke	Y	I-AdverseReaction
or	CC	or	or	or	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
.	.	.	.	.	N	O

Delay	NN	delay	delay	delay	N	O
in	IN	in	in	in	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
may	MD	may	may	may	N	O
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
permanent	JJ	permanent	permanent	perman	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
sequelae	NN	sequelae	sequela	sequela	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
PRES	NNP	pres	pres	pre	N	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Respiratory	JJ	respiratory	respiratory	respiratori	N	O
Effects	NNS	effects	effect	effect	N	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
reductions	NNS	reductions	reduction	reduct	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
forced	JJ	forced	forced	forc	N	I-AdverseReaction
expiratory	NN	expiratory	expiratory	expiratori	N	I-AdverseReaction
volume	NN	volume	volume	volum	N	I-AdverseReaction
over	IN	over	over	over	N	I-AdverseReaction
1	CD	1	1	1	N	I-AdverseReaction
second	JJ	second	second	second	N	I-AdverseReaction
(	(	(	(	(	N	O
FEV1	NNP	fev1	fev1	fev1	N	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
diffusion	NN	diffusion	diffusion	diffus	N	I-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
capacity	NN	capacity	capacity	capac	N	I-AdverseReaction
for	IN	for	for	for	N	I-AdverseReaction
carbon	NN	carbon	carbon	carbon	N	I-AdverseReaction
monoxide	NN	monoxide	monoxide	monoxid	N	I-AdverseReaction
(	(	(	(	(	N	O
DLCO	NNP	dlco	dlco	dlco	N	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
as	RB	as	a	as	N	O
early	RB	early	early	earli	N	O
as	IN	as	a	as	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
initiation	NN	initiation	initiation	initi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
reduction	NN	reduction	reduction	reduct	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
predicted	JJ	predicted	predicted	predict	N	O
values	NNS	values	value	valu	N	O
for	IN	for	for	for	N	I-AdverseReaction
FEV1	NNP	fev1	fev1	fev1	N	I-AdverseReaction
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
last	JJ	last	last	last	N	O
assessment	NN	assessment	assessment	assess	N	O
on	IN	on	on	on	N	O
drug	NN	drug	drug	drug	N	O
was	VBD	was	wa	wa	N	O
2.8%	CD	2.8%	2.8%	2.8%	N	B-Severity
for	IN	for	for	for	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
DLCO	NNP	dlco	dlco	dlco	N	B-AdverseReaction
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
reduction	NN	reduction	reduction	reduct	N	I-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
predicted	JJ	predicted	predicted	predict	N	O
values	NNS	values	value	valu	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
last	JJ	last	last	last	N	O
assessment	NN	assessment	assessment	assess	N	O
on	IN	on	on	on	N	O
drug	NN	drug	drug	drug	N	O
was	VBD	was	wa	wa	N	O
3.3%	CD	3.3%	3.3%	3.3%	N	B-Severity
for	IN	for	for	for	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
FEV1	NNP	fev1	fev1	fev1	N	I-AdverseReaction
appear	VBP	appear	appear	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
reversible	JJ	reversible	reversible	revers	N	B-Severity
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
information	NN	information	information	inform	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
the	DT	the	the	the	N	O
reversibility	NN	reversibility	reversibility	revers	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
DLCO	NNP	dlco	dlco	dlco	N	I-AdverseReaction
after	IN	after	after	after	N	O
drug	NN	drug	drug	drug	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
MS	NNP	ms	m	ms	Y	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Several	JJ	several	several	sever	N	O
patients	NNS	patients	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
unexplained	JJ	unexplained	unexplained	unexplain	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
extension	NN	extension	extension	extens	N	O
(	(	(	(	(	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
)	)	)	)	)	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

GILENYA	NNP	gilenya	gilenya	gilenya	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
tested	VBN	tested	tested	test	N	O
in	IN	in	in	in	N	O
MS	NNP	ms	m	ms	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
compromised	JJ	compromised	compromised	compromis	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Spirometric	JJ	spirometric	spirometric	spirometr	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
and	CC	and	and	and	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
DLCO	NNP	dlco	dlco	dlco	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
performed	VBN	performed	performed	perform	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
if	IN	if	if	if	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Liver	NNP	liver	liver	liver	N	O
Injury	NNP	injury	injury	injuri	Y	O

Elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

Recent	NNP	recent	recent	recent	N	O
(	(	(	(	(	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
within	IN	within	within	within	N	O
last	JJ	last	last	last	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
and	CC	and	and	and	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
levels	NNS	levels	level	level	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
available	JJ	available	available	avail	N	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
elevation	NN	elevation	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
to	TO	to	to	to	N	O
3	CD	3	3	3	N	B-Severity
-	:	-	-	-	N	I-Severity
fold	VBD	fold	fold	fold	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
(	(	(	(	(	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
)	)	)	)	)	N	I-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Elevations	NNS	elevations	elevation	elev	N	O
5	CD	5	5	5	N	O
-	:	-	-	-	N	O
fold	VBD	fold	fold	fold	N	O
the	DT	the	the	the	N	O
ULN	NNP	uln	uln	uln	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
4.5%	CD	4.5%	4.5%	4.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
elevations	NNS	elevations	elevation	elev	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
6	CD	6	6	6	N	O
to	TO	to	to	to	N	O
9	CD	9	9	9	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
was	VBD	was	wa	wa	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
elevation	NN	elevation	elevation	elev	N	O
exceeded	VBD	exceeded	exceeded	exceed	N	O
5	CD	5	5	5	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
ULN	NNP	uln	uln	uln	N	O
.	.	.	.	.	N	O

Serum	NNP	serum	serum	serum	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
levels	NNS	levels	level	level	N	O
returned	VBN	returned	returned	return	N	O
to	TO	to	to	to	N	O
normal	JJ	normal	normal	normal	N	O
within	IN	within	within	within	N	O
approximately	RB	approximately	approximately	approxim	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

Recurrence	NN	recurrence	recurrence	recurr	N	O
of	IN	of	of	of	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
rechallenge	NN	rechallenge	rechallenge	rechalleng	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Liver	NNP	liver	liver	liver	N	O
enzymes	NNS	enzymes	enzyme	enzym	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
suggestive	CD	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
unexplained	JJ	unexplained	unexplained	unexplain	N	O
nausea	NN	nausea	nausea	nausea	Y	O
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
dark	JJ	dark	dark	dark	N	O
urine	NN	urine	urine	urin	N	O
.	.	.	.	.	N	O

GILENYA	NNP	gilenya	gilenya	gilenya	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
significant	JJ	significant	significant	signific	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
preexisting	VBG	preexisting	preexisting	preexist	N	O
liver	JJ	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
when	WRB	when	when	when	N	O
taking	VBG	taking	taking	take	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
exposure	NN	exposure	exposure	exposur	N	O
is	VBZ	is	is	is	N	O
doubled	VBN	doubled	doubled	doubl	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	JJ	monitored	monitored	monitor	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
is	VBZ	is	is	is	N	O
greater	JJR	greater	greater	greater	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Fetal	NNP	fetal	fetal	fetal	N	O
Risk	NN	risk	risk	risk	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
animal	JJ	animal	animal	anim	N	B-Animal
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
may	MD	may	may	may	N	O
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
it	PRP	it	it	it	N	O
takes	VBZ	takes	take	take	N	O
approximately	RB	approximately	approximately	approxim	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
to	TO	to	to	to	N	O
eliminate	VB	eliminate	eliminate	elimin	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
body	NN	body	body	bodi	N	O
,	,	,	,	,	N	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
childbearing	VBG	childbearing	childbearing	childbear	N	O
potential	NN	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
use	VB	use	use	use	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
stopping	VBG	stopping	stopping	stop	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Blood	NNP	blood	blood	blood	N	O
Pressure	NN	pressure	pressure	pressur	N	O
Effects	NNS	effects	effect	effect	N	O

In	IN	in	in	in	N	O
MS	NNP	ms	m	ms	Y	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
average	JJ	average	average	averag	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
over	IN	over	over	over	N	O
placebo	NN	placebo	placebo	placebo	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
3	CD	3	3	3	N	B-Severity
mmHg	NNS	mmhg	mmhg	mmhg	N	I-Severity
in	IN	in	in	in	N	O
systolic	JJ	systolic	systolic	systol	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
approximately	RB	approximately	approximately	approxim	N	O
2	CD	2	2	2	N	B-Severity
mmHg	NNS	mmhg	mmhg	mmhg	N	I-Severity
in	IN	in	in	in	N	O
diastolic	JJ	diastolic	diastolic	diastol	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
first	RB	first	first	first	N	O
detected	VBN	detected	detected	detect	N	O
after	IN	after	after	after	N	O
approximately	RB	approximately	approximately	approxim	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
initiation	NN	initiation	initiation	initi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
persisting	VBG	persisting	persisting	persist	N	O
with	IN	with	with	with	N	O
continued	JJ	continued	continued	continu	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Blood	NNP	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Effects	NNPS	effects	effect	effect	N	O
Following	VBG	following	following	follow	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O

Fingolimod	NN	fingolimod	fingolimod	fingolimod	N	O
remains	VBZ	remains	remains	remain	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
has	VBZ	has	ha	ha	N	O
pharmacodynamic	JJ	pharmacodynamic	pharmacodynamic	pharmacodynam	N	O
effects	NNS	effects	effect	effect	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
lymphocyte	NN	lymphocyte	lymphocyte	lymphocyt	N	I-AdverseReaction
counts	NNS	counts	count	count	N	I-AdverseReaction
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
GILENYA	NNP	gilenya	gilenya	gilenya	N	O
.	.	.	.	.	N	O

Lymphocyte	NN	lymphocyte	lymphocyte	lymphocyt	N	O
counts	VBZ	counts	count	count	N	O
generally	RB	generally	generally	gener	N	O
return	VB	return	return	return	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
normal	JJ	normal	normal	normal	N	O
range	NN	range	range	rang	N	O
within	IN	within	within	within	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
stopping	VBG	stopping	stopping	stop	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
continuing	VBG	continuing	continuing	continu	N	O
pharmacodynamic	JJ	pharmacodynamic	pharmacodynamic	pharmacodynam	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
fingolimod	NN	fingolimod	fingolimod	fingolimod	N	O
,	,	,	,	,	N	O
initiating	VBG	initiating	initiating	initi	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
during	IN	during	during	dure	N	O
this	DT	this	this	thi	N	O
period	NN	period	period	period	N	O
warrants	NNS	warrants	warrant	warrant	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
considerations	NNS	considerations	consideration	consider	N	O
needed	VBN	needed	needed	need	N	O
for	IN	for	for	for	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
administration	NN	administration	administration	administr	N	O
(	(	(	(	(	N	O
e	FW	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
additive	JJ	additive	additive	addit	N	O
immunosuppressant	JJ	immunosuppressant	immunosuppressant	immunosuppress	N	B-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
)	)	)	)	)	N	O
[	VBP	[	[	[	N	O
see	JJ	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

